Analysis of current status and influencing factors of opportunistic infections in Crohn disease

doi:10.16138/j.1673-6087.2025.06.03

Abstract

Abstract:

Objective To explore the current status and influencing factors of opportunistic infections in Crohn disease. Methods Data on demographic characteristics, disease features, treatment regimens and laboratory results of 369 patients with Crohn disease admitted to a tertiary grade A hospital in Shanghai from January 2020 to August 2024 were retrospectively collected. Univariate analysis and multivariate Logistic regression were employed to identify the influencing factors of opportunistic infections in Crohn disease. Results The incidence of opportunistic infections in patients with Crohn disease was 32.25%. Specifically, the incidence rates of viral infections, bacterial infections, and multiple infections were 16%, 12.2%, and 3.8%, respectively. Multivariate Logistic regression analysis showed that low disease activity [odds ratio (OR)=3.22, 95% CI: 1.18−8.81, P=0.023], moderate disease activity (OR=7.16, 95% CI: 1.88−27.31, P=0.004), albumin < 30 g/L (OR=4.99, 95% CI: 2.04−12.18, P < 0.001), and C-reactive protein > 10 mg/L (OR=3.70, 95% CI: 1.27−10.78, P=0.016) were independent risk factors for Crohn disease complicated with Epstein-Barr virus infection. A Charlson comorbidity index score of 1 (OR=5.01, 95% CI: 1.51−16.60, P=0.008), albumin < 30 g/L (OR=3.45, 95% CI: 1.23−9.72, P=0.019), and C-reactive protein >10 mg/L (OR=13.06, 95% CI: 2.46−69.40, P=0.003) were independent risk factors for Crohn disease complicated with latent mycobacterium tuberculosis infection. C-reactive protein >10 mg/L (OR=20.41, 95% CI: 2.13−195.52, P=0.009) was an independent risk factor for Crohn disease complicated with multiple infections. Conclusions Disease activity, co-existing chronic diseases, hypoalbuminemia, and elevated C-reactive protein levels are predictive factors for opportunistic infections in patients with Crohn disease. Active prevention as well as early diagnosis and treatment should be implemented for these patients at risk.

Key words: Crohn disease, Opportunistic infection, Influencing factors

CLC Number:

R574.62

CAI Hui, LI Yousheng, HUANG Yuhua, XU Jingjing, LIU Qingfen, GU Fen. Analysis of current status and influencing factors of opportunistic infections in Crohn disease[J]. Journal of Internal Medicine Concepts & Practice, 2026, 20(06): 440-448.

Figures/Tables 5

Table 1

Table 2

Univariate analysis of factors associated with opportunistic infections in patients with CD[n(%)/$\bar {\boldsymbol{x}} $±s/M(Q1,Q3)]

变量	EBV感染			LTBI			其他细菌感染			多重感染
变量	无（n=320）	有（n=49）	P	无（n=337）	有（n=27）	P	无（n=351）	有（n=18）	P	无（n=355）	有（n=14）	P
A1：确诊年龄≤16岁；A2：确诊年龄17～40岁；A3：确诊年龄>40岁。L1：回肠末端；L2：结肠；L3：回结肠；L4：上消化道。B1：非狭窄非穿透；B2：狭窄；B3：穿透；P：肛周病变。
年龄(岁)	39.09 ± 13.25	39.90 ± 11.12	0.685	39.01 ± 12.84	41.59 ± 14.63	0.319	39.00 ± 13.01	43.06 ± 11.94	0.196	39.09 ± 12.97	41.86 ± 13.32	0.435
性别[n(%)]			0.595			0.968			0.715			0.894
男性	202 (63.12)	29 (59.18)		214 (62.57)	17 (62.96)		219 (62.39)	12 (66.67)		222 (62.54)	9 (64.29)
女性	118 (36.88)	20 (40.82)		128 (37.43)	10 (37.04)		132 (37.61)	6 (33.33)		133 (37.46)	5 (35.71)
BMI (kg/m²)	20.13 ± 3.43	18.94 ± 2.64	0.021	20.01 ± 3.32	19.46 ± 3.80	0.408	20.07 ± 3.36	18.10 ± 2.71	0.015	20.03 ± 3.38	18.50 ± 1.96	0.093
肠内营养 [n(%)]			0.004			0.984			0.005			0.222
无	127 (39.69)	9 (18.37)		126 (36.84)	10 (37.04)		135 (38.46)	1 (5.56)		133 (37.46)	3 (21.43)
有	193 (60.31)	40 (81.63)		216 (63.16)	17 (62.96)		216 (61.54)	17 (94.44)		222 (62.54)	11 (78.57)
NRS2002评分(分) [n(%)]			0.007			0.434			0.188			0.086
0	126 (39.38)	9 (18.37)		125 (36.55)	10 (37.04)		132 (37.61)	3 (16.67)		134 (37.75)	1 (7.14)
1	1 (0.31)	0 (0.00)		1 (0.29)	0 (0.00)		1 (0.28)	0 (0.00)		1 (0.28)	0 (0.00)
2	74 (23.12)	21 (42.86)		91 (26.61)	4 (14.81)		91 (25.93)	4 (22.22)		91 (25.63)	4 (28.57)
3	107 (33.44)	16 (32.65)		112 (32.75)	11 (40.74)		112 (31.91)	11 (61.11)		114 (32.11)	9 (64.29)
4	11 (3.44)	2 (4.08)		11 (3.22)	2 (7.41)		13 (3.70)	0 (0.00)		13 (3.66)	0 (0.00)
5	1 (0.31)	1 (2.04)		2 (0.58)	0 (0.00)		2 (0.57)	0 (0.00)		2 (0.56)	0 (0.00)
病程 (月)	76.56 ± 70.94	84.31 ± 80.75	0.486	79.07 ± 73.42	58.85 ± 52.85	0.162	75.30 ± 70.67	122.17 ± 89.32	0.007	76.51 ± 71.39	105.07 ± 90.29	0.147
CCI评分 (分)[n(%)]			0.168			0.016			0.738			0.453
0	289 (90.31)	45 (91.84)		314 (91.81)	20 (74.07)		318 (90.60)	16 (88.89)		322 (90.70)	12 (85.71)
1	27 (8.44)	2 (4.08)		22 (6.43)	7 (25.93)		27 (7.69)	2 (11.11)		27 (7.61)	2 (14.29)
2	3 (0.94)	1 (2.04)		4 (1.17)	0 (0.00)		4 (1.14)	0 (0.00)		4 (1.13)	0 (0.00)
3	1 (0.31)	1 (2.04)		2 (0.58)	0 (0.00)		2 (0.57)	0 (0.00)		2 (0.56)	0 (0.00)
蒙特利尔分型-年龄分型[n(%)]			0.535			0.022			0.616			0.173
A1	18 (5.62)	1 (2.04)		18 (5.26)	1 (3.70)		18 (5.13)	1 (5.56)		18 (5.07)	1 (7.14)
A2	219 (68.44)	36 (73.47)		242 (70.76)	13 (48.15)		241 (68.66)	14 (77.78)		248 (69.86)	7 (50.00)
A3	83 (25.94)	12 (24.49)		82 (23.98)	13 (48.15)		92 (26.21)	3 (16.67)		89 (25.07)	6 (42.86)
蒙特利尔分型-疾病部位[n(%)]			0.805			0.250			0.399			0.527
L1	95 (29.69)	16 (32.65)		107 (31.29)	4 (14.81)		108 (30.77)	3 (16.67)		108 (30.42)	3 (21.43)
L2	23 (7.19)	3 (6.12)		23 (6.73)	3 (11.11)		26 (7.41)	0 (0.00)		26 (7.32)	0 (0.00)
L3	176 (55.00)	25 (51.02)		182 (53.22)	19 (70.37)		188 (53.56)	13 (72.22)		192 (54.08)	9 (64.29)
L1+L4	3 (0.94)	1 (2.04)		4 (1.17)	0 (0.00)		4 (1.14)	0 (0.00)		4 (1.13)	0 (0.00)
L3+L4	23 (7.19)	4 (8.16)		26 (7.60)	1 (3.70)		25 (7.12)	2 (11.11)		25 (7.04)	2 (14.29)
蒙特利尔分型-疾病行为[n(%)]			0.368			0.389			0.013			0.009
B1	62 (19.38)	6 (12.24)		65 (19.01)	3 (11.11)		68 (19.37)	0 (0.00)		68 (19.15)	0 (0.00)
B2	157 (49.06)	22 (44.90)		161 (47.08)	18 (66.67)		172 (49.00)	7 (38.89)		173 (48.73)	6 (42.86)
B3	48 (15.00)	12 (24.49)		58 (16.96)	2 (7.41)		57 (16.24)	3 (16.67)		56 (15.77)	4 (28.57)
B1+P	2 (0.62)	0 (0.00)		2 (0.58)	0 (0.00)		2 (0.57)	0 (0.00)		1 (0.28)	1 (7.14)
B2+P	24 (7.50)	6 (12.24)		29 (8.48)	1 (3.70)		26 (7.41)	4 (22.22)		30 (8.45)	0 (0.00)
B3+P	27 (8.44)	3 (6.12)		27 (7.89)	3 (11.11)		26 (7.41)	4 (22.22)		27 (7.61)	3 (21.43)
疾病活动度[n(%)]			<0.001			0.010			0.020			0.002
缓解期	270 (84.38)	23 (46.94)		278 (81.29)	15 (55.56)		283 (80.63)	10 (55.56)		287 (80.85)	6 (42.86)
轻度活　动期	36 (11.25)	13 (26.53)		41 (11.99)	8 (29.63)		45 (12.82)	4 (22.22)		43 (12.11)	6 (42.86)
中度活　动期	12 (3.75)	11 (22.45)		19 (5.56)	4 (14.81)		20 (5.70)	3 (16.67)		22 (6.20)	1 (7.14)
重度活　动期	2 (0.62)	2 (4.08)		4 (1.17)	0 (0.00)		3 (0.85)	1 (5.56)		3 (0.85)	1 (7.14)
5-氨基水杨酸类药物用药时长（月）	0.00 (0.00, 15.00)	2.00 (0.00, 36.00)	0.257	0.00 (0.00, 17.00)	7.00 (0.00, 24.00)	0.311	0.00 (0.00, 17.00)	1.00 (0.00, 57.00)	0.298	0.00 (0.00, 20.00)	0.00 (0.00, 12.50)	0.569
类固醇类药物用药时长（月）	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.784	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.842	0.00 (0.00, 0.00)	0.00 (0.00, 39.75)	0.041	0.00 (0.00, 0.00)	0.00 (0.00, 0.00)	0.632
免疫抑制剂用药时长 (月)	18.71 ± 36.69	16.20 ± 37.32	0.657	18.68 ± 37.08	14.56 ± 32.39	0.575	18.11 ± 36.59	23.67 ± 40.24	0.532	18.35 ± 36.64	19.00 ± 40.52	0.948
生物制剂用药时长（月）	14.00 (4.00, 29.75)	2.00 (0.00, 16.00)	<0.001	14.00 (2.00, 29.00)	4.00 (1.00, 10.00)	0.004	13.00 (2.00, 28.50)	4.50 (1.75, 9.25)	0.035	12.00 (2.00, 28.00)	5.00 (0.00, 20.75)	0.204
联合用药 [n(%)]			0.786			0.092			0.974			0.525
无	293 (91.56)	46 (93.88)		317 (92.69)	22 (81.48)		323 (92.02)	16 (88.89)		325 (91.55)	14 (100.00)
有	27 (8.44)	3 (6.12)		25 (7.31)	5 (18.52)		28 (7.98)	2 (11.11)		30 (8.45)	0 (0.00)
白细胞计数（×10⁹/L）[n(%)]			0.001			0.127			0.122			0.259
<4	49 (15.31)	6 (12.24)		50 (14.62)	5 (18.52)		53 (15.10)	2 (11.11)		52 (14.65)	3 (21.43)
4～10	241 (75.31)	29 (59.18)		254 (74.27)	16 (59.26)		259 (73.79)	11 (61.11)		262 (73.80)	8 (57.14)
>10	30 (9.38)	14 (28.57)		38 (11.11)	6 (22.22)		39 (11.11)	5 (27.78)		41 (11.55)	3 (21.43)
中性粒细胞计数（×10⁹/L）[n(%)]			0.011			0.110			0.028			0.072
<2	28 (8.75)	5 (10.20)		29 (8.48)	4 (14.81)		31 (8.83)	2 (11.11)		30 (8.45)	3 (21.43)
2～7	256 (80.00)	31 (63.27)		270 (78.95)	17 (62.96)		277 (78.92)	10 (55.56)		279 (78.59)	8 (57.14)
>7	36 (11.25)	13 (26.53)		43 (12.57)	6 (22.22)		43 (12.25)	6 (33.33)		46 (12.96)	3 (21.43)
淋巴细胞计数（×10⁹/L）[n(%)]			0.156			0.165			0.084			0.470
<0.8	43 (13.44)	12 (24.49)		54 (15.79)	1 (3.70)		49 (13.96)	6 (33.33)		52 (14.65)	3 (21.43)
0.8～4.0	276 (86.25)	37 (75.51)		287 (83.92)	26 (96.30)		301 (85.75)	12 (66.67)		302 (85.07)	11 (78.57)
>4.0	1 (0.31)	0 (0.00)		1 (0.29)	0 (0.00)		1 (0.28)	0 (0.00)		1 (0.28)	0 (0.00)
红细胞沉降率（mm/h）[n(%)]			0.338			0.716			0.280			0.091
≤20	218 (68.12)	30 (61.22)		229 (66.96)	19 (70.37)		238 (67.81)	10 (55.56)		242 (68.17)	6 (42.86)
>20	102 (31.88)	19 (38.78)		113 (33.04)	8 (29.63)		113 (32.19)	8 (44.44)		113 (31.83)	8 (57.14)
白蛋白（g/L）[n(%)]			< 0.001			< 0.001			< 0.001			0.011
<30	41 (12.81)	32 (65.31)		55 (16.08)	18 (66.67)		63 (17.95)	10 (55.56)		66 (18.59)	7 (50.00)
≥30	279 (87.19)	17 (34.69)		287 (83.92)	9 (33.33)		288 (82.05)	8 (44.44)		289 (81.41)	7 (50.00)
血红蛋白（g/L）[n(%)]			0.007			0.329			< 0.001			0.089
≤110	106 (33.12)	26 (53.06)		120(35.09)	12 (44.44)		119 (33.90)	13(72.22)		124 (34.93)	8 (57.14)
>110	214(66.88)	23 (46.94)		222 (64.91)	15(55.56)		232 (66.10)	5 (27.78)		231 (65.07)	6 (42.86)
CRP（mg/L）[n(%)]			< 0.001			< 0.001			< 0.001			< 0.001
≤10	235(73.44)	8(16.33)		241(70.47)	2 (7.41)		243 (69.23)	0 (0.00)		242 (68.17)	1 (7.14)
>10	85(26.56)	41(83.67)		101(29.53)	25(92.59)		108(30.77)	18(100.00)		113(31.83)	13(92.86)

Table 2

Table 3

Table 4

Table 5

References 22

[1]	Torres J, Mehandru S, Colombel JF, et al. Crohn’s disease[J]. Lancet, 2017, 389(10080):1741-1755. doi: 10.1016/S0140-6736(16)31711-1
[2]	周联玉, 缪应雷. 炎症性肠病合并EB病毒感染的研究进展[J]. 中国当代医药, 2020, 27(26):24-27. doi: 10.3969/j.issn.1674-4721.2020.26.007
	Zhou LY, Miao YL. Research progression inflammatory bowel disease combined with Epstein-Barr virus infection[J]. China Modern Medicine, 2020, 27(26):24-27. doi: 10.3969/j.issn.1674-4721.2020.26.007
[3]	Lee J. Cytomegalovirus infection in patients with inflammatory bowel disease[J]. Korean J Gastroenterol, 2022, 80(2):60-65. doi: 10.4166/kjg.2022.094
[4]	Shin SH, Park SH. Viral hepatitis in patients with inflammatory bowel disease[J]. Korean J Gastroenterol, 2022, 80(2):51-59. doi: 10.4166/kjg.2022.096
[5]	中华医学会消化病学分会炎症性肠病学组, 中国炎症性肠病诊疗质量控制评估中心. 中国克罗恩病诊治指南（2023年·广州）[J]. 胃肠病学, 2024, 29(4):200-235. doi: 10.3760/cma.j.cn311367-20240109-00010
	Inflammatory Bowel Disease Group of Chinese Society of Gastroenterology of Chinese Medical Association, Inflammatory Bowel Disease Quality Control Center of China. Chinese clinical practice guideline on the management of Crohn′s disease (2023, Guangzhou)[J]. Chin J Gastroenterol, 2024, 29(4):200-235. doi: 10.3760/cma.j.cn311367-20240109-00010
[6]	杨少武, 吴刚. 克罗恩病患者合并院内感染的危险因素分析[J]. 中华实验和临床感染病杂志（电子版）, 2015, 9(3):390-392. doi: 10.3877/cma.j.issn.1674-1358.2015.03.024
	Yang SW, Wu G. Risk factors for nosocomial infections in patients with Crohn’s disease[J]. Chin J Exp Clin Infect Dis (Electronic Edition), 2015, 9(3):390-392. doi: 10.3877/cma.j.issn.1674-1358.2015.03.024
[7]	Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(1):56-66. doi: 10.1038/s41575-020-00360-x
[8]	Park SH. Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?[J]. Intest Res, 2022, 20(2):159-164. doi: 10.5217/ir.2021.00115
[9]	Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21^st century: a systematic review of population-based studies[J]. Lancet, 2017, 390(10114):2769-2778. doi: 10.1016/S0140-6736(17)32448-0
[10]	Mak WY, Zhao M, Ng SC, et al. The epidemiology of inflammatory bowel disease: east meets west[J]. J Gastroenterol Hepatol, 2020, 35(3):380-389. doi: 10.1111/jgh.14872
[11]	杨红, 金梦, 张慧敏, 等. 炎性肠病并发机会性感染及其对预后的影响[J]. 中华临床免疫和变态反应杂志, 2019, 13(2):104-107. doi: 10.3969/j.issn.1673-8705.2019.02.003
	Yang H, Jin M, Zhang HM, et al. Opportunistic infections in inflammatory bowel disease and its impact on prognosis[J]. Chin J Allergy Clin Immunol, 2019, 13(2):104-107. doi: 10.3969/j.issn.1673-8705.2019.02.003
[12]	Caio G, Lungaro L, Caputo F, et al. Nutritional treatment in Crohn’s disease[J]. Nutrients, 2021, 13(5):1628. doi: 10.3390/nu13051628
[13]	中华医学会消化病学分会炎症性肠病学组, 中华医学会肠外与肠内营养学分会胃肠病与营养协作组. 炎症性肠病营养支持治疗专家共识（第二版）[J]. 中华炎性肠病杂志（中英文）, 2018, 2(3):154-172. doi: 10.3760/cma.j.issn.0578-1426.2013.12.025
	Inflammatory Bowel Disease Group of Chinese Society of Gastroenterology of Chinese Medical Association, Gastroenterology and Nutrition Cooperative Group of Parenteral and Intestinal Nutrition Branch of Chinese Medical Association. Chinese experts consensus on nutrition support therapy in inflammatory bowel disease (the second edition)[J]. Chin J Inflamm Bowel Dis, 2018, 2(3):154-172. doi: 10.3760/cma.j.issn.0578-1426.2013.12.025
[14]	严智亮, 李梦迪, 郑松柏. 克罗恩病患者营养不良特点和营养治疗进展[J]. 中华消化杂志, 2023, 43(1):65-69.
	Yan ZL, Li MD, Zheng SB. Malnutrition features and advances in nutritional therapy for patients with Crohn’s disease[J]. Chin J Dig, 2023, 43(1):65-69.
[15]	李玥颖, 余炯言, 曾志文, 等. C反应蛋白在脓毒血症中的关键作用及研究进展[J]. 医药前沿, 2025, 15(15):28-31.
	Li YY, Yu JY, Zeng ZW, et al. Key role and research progress of C-reactive protein in sepsis[J]. Journal of Frontiers of Medicine, 2025, 15(15):28-31.
[16]	邹俊, 王道协, 金冬花, 等. 血清IL-6、PCT、CRP联合检测诊断脓毒症的价值[J]. 临床医学, 2025, 45(5):74-76. doi: 10.19528/j.issn.1003-3548.2025.05.023
	Zou J, Wang DX, Jin DH, et al. Diagnostic value of combined detection of serum IL-6, PCT, and CRP for sepsis[J]. Clinical Medicine, 2025, 45(5):74-76. doi: 10.19528/j.issn.1003-3548.2025.05.023
[17]	Sproston NR, Ashworth JJ. Role of C-reactive protein at sites of inflammation and infection[J]. Front Immunol, 2018, 9: 754. doi: 10.3389/fimmu.2018.00754
[18]	Berbudi A, Rahmadika N, Tjahjadi AI, et al. Type 2 diabetes and its impact on the immune system[J]. Curr Diabetes Rev, 2020, 16(5):442-449.
[19]	Wang W, Chen X, Pan J, et al. Epstein-Barr virus and human cytomegalovirus infection in intestinal mucosa of Chinese patients with inflammatory bowel disease[J]. Front Microbiol, 2022, 13: 915453. doi: 10.3389/fmicb.2022.915453
[20]	周三喜. HMGCS2、PPARγ在炎症性肠病患者肠粘膜的表达与活性[D]. 2011. 广州: 南方医科大学.
	Zhou SX. Expression and activity of HMGCS2 and PPARγ in the intestinal mucosa of patients with inflammatory bowel disease [D]. 2011. Guangzhou: Southern Medical University.
[21]	Núñez Ortiz A, Rojas Feria M, de la Cruz Ramírez MD, et al. Impact of Epstein-Barr virus infection on inflammatory bowel disease (IBD) clinical outcomes[J]. Rev Esp Enferm Dig, 2022, 114(5):259-265.
[22]	Beaugerie L, Rahier JF, Kirchgesner J. Predicting, preventing, and managing treatment-related complications in patients with inflammatory bowel diseases [J]. Clin Gastroenterol Hepatol, 2020, 18(6):1324-1335.

机会性感染	例数（百分比）[n（%）]
病毒感染	59（15.99）
EBV	49（13.28）
CMV	5（1.36）
HBV	5（1.36）
细菌感染	45（12.20）
LTBI	27（7.32）
其他细菌	18（4.88）
真菌感染	1（0.27）
多重感染	14（3.79）
EBV合并CMV	7（1.90）
EBV合并LTBI	6（1.63）
EBV合并肺炎克雷伯杆菌	1（0.27）

变量	β	SE	Z	P	OR (95%CI)
Inf：下确界。
BMI	−0.21	0.14	−1.48	0.140	0.81 (0.62 ~ 1.07)
肠内营养
无（参照）					1.00
有	0.35	0.49	0.72	0.472	1.42 (0.54 ~ 3.73)
NRS2002评分（分）
0（参照）					1.00
1	−13.01	1455.40	−0.01	0.993	0.00 (0.00 ~ inf)
2	0.52	0.68	0.77	0.444	1.68 (0.44 ~ 6.37)
3	−1.44	1.05	−1.37	0.171	0.24 (0.03 ~ 1.86)
4	−0.95	1.36	−0.70	0.486	0.39 (0.03 ~ 5.59)
5	1.07	2.66	0.40	0.689	2.91 (0.02 ~ 537.19)
疾病活动度
缓解期（参照）					1.00
轻度活动期	1.16	0.51	2.25	0.025	3.18 (1.16 ~ 8.70)
中度活动期	1.91	0.70	2.73	0.006	6.77 (1.71 ~ 26.81)
重度活动期	0.07	1.24	0.06	0.954	1.07 (0.10 ~ 12.11)
生物制剂用药时长	−0.02	0.01	−1.03	0.304	0.99 (0.96 ~ 1.01)
白细胞计数（×10⁹/L）
4～10（参照）					1.00
<4	0.58	0.78	0.74	0.459	1.79 (0.39 ~ 8.29)
>10	1.65	0.97	1.70	0.090	5.21 (0.77 ~ 35.13)
中性粒细胞计数（×10⁹/L）
2～7（参照）					1.00
<2	−0.93	0.90	−1.04	0.300	0.40 (0.07 ~ 2.29)
>7	−0.74	0.97	−0.77	0.442	0.48 (0.07 ~ 3.16)
白蛋白（g/L）
≥30（参照）					1.00
<30	1.60	0.46	3.50	<.001	4.95 (2.02 ~ 12.10)
血红蛋白（g/L）
>110（参照）					1.00
≤110	−0.60	0.48	−1.23	0.219	0.55 (0.21 ~ 1.43)

变量	β	SE	Z	P	OR (95%CI)
Inf：下确界。
CRP（mg/L）
≤10（参照）					1.00
>10	1.33	0.55	2.42	0.015	3.77 (1.29 ~ 11.02)
CCI评分（分）
0（参照）					1.00
1	1.76	0.62	2.86	0.004	5.84 (1.75 ~ 19.52)
2	−14.26	1829.19	−0.01	0.994	0.00 (0.00 ~ inf)
3	−16.07	2356.56	-0.01	0.995	0.00 (0.00 ~inf)
疾病活动度
缓解期（参照）					1.00
轻度活动期	0.44	0.55	0.80	0.425	1.55 (0.53 ~ 4.59)
中度活动期	-0.07	0.69	−0.10	0.918	0.93 (0.24 ~ 3.60)
重度活动期	−16.52	1976.50	−0.01	0.993	0.00 (0.00 ~ inf)
生物制剂用药时长	-0.04	0.02	−1.94	0.052	0.96 (0.92 ~ 1.00)
白蛋白（g/L）
≥30（参照）					1.00
<30	1.18	0.53	2.22	0.026	3.27 (1.15 ~ 9.28)
CRP（mg/L）
≤10（参照）					1.00
>10	2.50	0.84	2.97	0.003	12.15 (2.33 ~ 63.23)

变量	β	SE	Z	P	OR (95%CI)
Inf：下确界。
蒙特利尔分型-疾病行为
B1（参照）					1.00
B2	−18.59	4291.23	0.01	0.997	0(0.00 ~inf)
B3	−1.01	0.89	0.01	0.258	0.36(0.063 ~ 2.10)
B1+P	−0.35	0.95	0.01	0.714	0.71(0.11 ~ 4.52)
B2+P	2.86	2.41	0	0.235	17.53 (0.16 ~ 1978.01）
B3+P	−19.27	6733.65	0.01	0.998	0(0.00 ~ inf)
疾病活动度
缓解期（参照）					1.00
轻度活动期	1.12	0.63	1.79	0.074	3.08 (0.90 ~ 10.53)
中度活动期	−0.40	1.12	−0.36	0.723	0.67 (0.08 ~ 6.02)
重度活动期	1.50	1.28	1.18	0240	4.49 (0.37 ~ 55.14)
白蛋白（g/L）
≥30（参照）					1.00
<30	−0.10	0.62	-0.16	0.871	0.90 (0.27 ~ 3.03)
CRP（mg/L）
≤10（参照）					1.00
>10	3.13	1.12	2.83	0.005	22.92 (2.62 ~ 200.35)